Aprotinin; An economy of truth?

Journal of Thoracic and Cardiovascular Surgery

Volumn 136, Issue 3, 2008, Pages 798-799

  Royston, David ^a  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; APROTININ;

BLEEDING; CARDIOPULMONARY BYPASS; ERYTHROCYTE TRANSFUSION; FOOD AND DRUG ADMINISTRATION; HEART FAILURE; HEART INFARCTION; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LETTER; MEDICAL INFORMATION; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVASCULARIZATION; RISK ASSESSMENT; SCORING SYSTEM;

APROTININ; HEMOSTATICS; HUMANS;

EID: 52049107111     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2008.05.023     Document Type: Letter

References (6)

1. Sundt T.M. The demise of aprotinin: Our share of the blame. J Thorac Cardiovasc Surg 135 (2008) 729-731
2. Westaby S. Aprotinin: Twenty-five years of claim and counterclaim. J Thorac Cardiovasc Surg 135 (2008) 487-491
3. Mangano D.T., Tudor I.C., and Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 354 (2006) 353-365
4. Levenson.ppt & Cyns.ppt in Cardiovascular and Renal Drugs Advisory Committee (CRDAC) in Joint Session with the Drug Safety and Risk Management Advisory Committee (DSaRM). Slides Found at www.fda.gov/ohrms/dockets/ac/07/slides2007-4316s1-00-index.htm. Accessed July 5th 2008.
5. Furnary A.P., Wu Y., Hiratzka L.F., Grunkemeier G.L., and Page III U.S. Aprotinin does not increase the risk of renal failure in cardiac surgery patients. Circulation 116 11 Suppl (2007) I127-I133
6. Shaw A.D., Stafford-Smith M., White W.D., Phillips-Bute B., Swaminathan M., Milano C., et al. The effect of aprotinin on outcome after coronary-artery bypass grafting. N Engl J Med 358 (2008) 784-793